The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The new algorithm, called TOPSPIN, complements the company's MMprofiler test. It is considering making TOPSPIN-generated data available to its MMprofiler patients.
Mergers and acquisitions in the omics space rose for the second year in a row, but the increase was significantly less than the 33 percent uptick in 2015 deals.
The company plans to use Thermo Fisher Scientific's newly launched PharmacoScan array-based platform for its testing.
The consortium aims to profile up to 800 multiple myeloma patient samples using the Affymetrix platform with a goal of developing a list of predictive biomarkers.
The first six months of the year have already seen some major deals announced, including big acquisitions by Abbott and Thermo Fisher Scientific.
Three major European genomics service providers have founded a consortium to offer cost-effective, whole-genome genotyping on a new Illumina SNP array.
The GenomeWeb Index rose more than 6 percent in March, in line with the Dow and the Nasdaq, and significantly outperforming the Nasdaq Biotech Index.
After Affymetrix's shareholders approved the acquisition, Thermo Fisher was able to close the deal for a total purchase price of $1.3 billion.
Dog DNA testing finds that some purebreds might not truly be purebreds, Inside Edition reports.
Mary Beckerle has returned as director of the Huntsman Cancer Institute, according to ScienceInsider.
Smithsonian Magazine reports that environmental DNA sampling can be used to track elusive organisms.
In Genome Research this week: repetitive satellite DNA in the fruit fly, transcriptome map assembly pipeline, and more.